Spero Therapeutics, Inc.
SPRO · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $105,808 | $162,478 | $39,871 | $55,659 |
| - Cash | $48,616 | $31,194 | $48,887 | $52,889 |
| + Debt | $3,351 | $3,615 | $3,960 | $4,297 |
| Enterprise Value | $60,543 | $134,899 | -$5,056 | $7,067 |
| Revenue | $3,048 | $11,802 | $5,874 | $15,044 |
| % Growth | -74.2% | 100.9% | -61% | – |
| Gross Profit | $3,048 | $11,802 | -$7,732 | -$79,590 |
| % Margin | 100% | 100% | -131.6% | -529% |
| EBITDA | -$7,382 | -$2,361 | -$14,556 | -$20,848 |
| % Margin | -242.2% | -20% | -247.8% | -138.6% |
| Net Income | -$7,382 | -$1,700 | -$13,866 | -$20,888 |
| % Margin | -242.2% | -14.4% | -236.1% | -138.8% |
| EPS Diluted | -0.13 | -0.03 | -0.25 | -0.39 |
| % Growth | -329% | 87.9% | 35.9% | – |
| Operating Cash Flow | $17,422 | -$17,693 | -$4,002 | -$23,401 |
| Capital Expenditures | $0 | $0 | $0 | $0 |
| Free Cash Flow | $17,422 | -$17,693 | -$4,002 | -$23,401 |